Difference between revisions of "CD38"
m |
|||
(One intermediate revision by one other user not shown) | |||
Line 1: | Line 1: | ||
{| class="toccolours" border="1" style="float: left; clear: right; margin: 0 0 1em 1em; border-collapse: collapse;" | {| class="toccolours" border="1" style="float: left; clear: right; margin: 0 0 1em 1em; border-collapse: collapse;" | ||
− | ! | + | ! {infobox header}| '''{{PAGENAME}}''' |
− | |||
− | |||
|- | |- | ||
| Substrate peptide name | | Substrate peptide name | ||
Line 49: | Line 47: | ||
|- | |- | ||
− | | | + | | {infobox header} | |
|- | |- | ||
|} | |} | ||
[[Category:Tissue transglutaminase|*]] | [[Category:Tissue transglutaminase|*]] |
Latest revision as of 11:30, 10 March 2015
CD38 | |
---|---|
Substrate peptide name | CD38 |
Synonyms | ADP-ribosyl cyclase 1 |
Determination type | In situ/In vitro |
Source | Homo sapiens |
Subcellular localization | Plasma membrane |
Swissprot ID | P28907 |
Reactive glutamines | Not determined yet |
Reactive lysines | Not determined yet |
Substrate sequence | |
Structure | 1LBE |
Surface accessibility | |
Disorder prediction | IUPred |
Reference | PMID:8663150 |
Notes | TG2 catalyze the dimerization and multimerization of CD38 protein
Upon crosslinking by TG2 the cyclase activity increases and the hydrolase activity decreases |